The YAP1–NMU Axis Is Associated with Pancreatic Cancer Progression and Poor Outcome: Identification of a Novel Diagnostic Biomarker and Therapeutic Target
Wonbeak Yoo(Korea Research Institute of Bioscience and Biotechnology), Seok‐Ho Kim(Kangwon National University), Dana Jung(Dong-A University), Eunsung Jun(Asan Medical Center), Ji-Su Kim(Korea Research Institute of Bioscience and Biotechnology), Kwang Hwa Jung(Baylor College of Medicine), Yun-Yong Park(Ulsan College), Sangmin Lee(Korea Research Institute of Bioscience and Biotechnology), Kyung Hee Noh(Korea Research Institute of Bioscience and Biotechnology), Jaemin Lee(Korea Research Institute of Bioscience and Biotechnology), Song Cheol Kim(Ulsan College)
Cited by 27
Related Papers
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
|Gastroenterology|2015|472
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299
A 3D-printed local drug delivery patch for pancreatic cancer growth suppression
|Journal of Controlled Release|2016|260